Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Nat Rev Clin Oncol
.
2018 Apr;15(4):218.
doi: 10.1038/nrclinonc.2018.20.
Epub 2018 Feb 13.
Authors
Sattva S Neelapu
1
,
Sudhakar Tummala
2
,
Partow Kebriaei
3
,
William Wierda
4
,
Frederick L Locke
5
,
Yi Lin
6
,
Nitin Jain
4
,
Naval Daver
4
,
Alison M Gulbis
7
,
Sherry Adkins
1
,
Katayoun Rezvani
3
,
Patrick Hwu
8
,
Elizabeth J Shpall
3
Affiliations
1
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center.
2
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center.
3
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center.
4
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
5
Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.
6
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
7
Division of Pharmacy, The University of Texas MD Anderson Cancer Center.
8
Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
PMID:
29434334
PMCID:
PMC6716606
DOI:
10.1038/nrclinonc.2018.20
No abstract available
Publication types
Comment
MeSH terms
Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive*
Receptors, Chimeric Antigen*
Substances
Receptors, Chimeric Antigen
Grants and funding
K23 CA201594/CA/NCI NIH HHS/United States
P30 CA016672/CA/NCI NIH HHS/United States